The two medications behind every program
Two medications sit behind almost every GLP-1 telehealth program: tirzepatide and semaglutide. As of November 20, 2026, compounded tirzepatide costs $85.58 to $399 and semaglutide $75.58 to $299 per billing cycle month to month, all-in, at programs that print a comparable price; brand Zepbound vials cost $299 to $449 and Wegovy pens $349 bought direct.
Released · Last reviewed · how we verify
Tirzepatide
Zepbound and Mounjaro; SURMOUNT-5 showed 20.2% average weight loss against 13.7% for semaglutide. Compounded from $85.58 a month all-in (Collective, with its yearly membership).
Semaglutide
Wegovy (pen, HD pen and pill), Ozempic and Rybelsus. Compounded from $75.58 a month all-in; the Wegovy pill costs $149 to $299 bought direct.
Price check by drug
Price check, compounded tirzepatide month to month and all-in (read November 20, 2026): Collective charges $69 a month plus a $199 annual membership (about $85.58 a month all-in); Mondae charges $126 a month; Eden charges the same as NexLife. Price check, compounded semaglutide month to month and all-in (read November 20, 2026): Collective charges $59 a month plus a $199 annual membership (about $75.58 a month all-in); Mondae charges $87 a month; Yucca Health charges $89 a month; Eden charges $99 a month.
Whether either drug suits you is a clinical decision for you and a licensed prescriber. Compounded versions are not FDA-approved and are not the same products as the brands.
Frequently asked
Are compounded tirzepatide and semaglutide legal and FDA-approved in 2026?
Compounded tirzepatide and semaglutide are not FDA-approved, and as of November 20, 2026 they reach U.S. patients as prescriptions for an individual patient filled by state-licensed 503A compounding pharmacies; they are made with the drug in Zepbound or Wegovy but are not the same product. FDA proposed on April 30, 2026 not to place either drug on the 503B bulks list, and no final decision was found as of November 20. Warning letters continue, including letter 737905 to telehealth seller RonanRx on October 30, 2026.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)